Efficacy of Povidone-Iodine Nasal And Oral Antiseptic Preparations Against Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2)

Pelletier, Jesse; Tessema, Belachew; Westover, Jonna B.; Frank, Samantha; Brown, Seth M.; Capriotti, Joseph

doi:10.1101/2020.05.25.20110239

Cited by 27 publications

(60 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Iodine is established as having a broad-spectrum antimicrobial activity against bacterial, viral, fungal and protozoal pathogens and has been used as an antiseptic for the prevention of infection and the treatment of wounds for decades. PVP-I currently has the best antiviral activity against SARS-CoV and MERS-CoV (9), and its virucidal in vitro activity against the novel, SARS-CoV-2 virus has been demonstrated recently (12). This paper aimed to demonstrate that the novel Iodine-V in EID as an active virucidal ingredient is as efficacious as PVP-I and potentially safer.…”

Section: Discussionmentioning

confidence: 99%

“…Before testing, a virus stock of SARS-CoV-2 (USAWA1/2020 strain) sourced from the CDC following its original isolation from an infected patient in Washington state, USA (WA-1 strain BEI #NR-52281 strain), was prepared according to Pelletier and colleagues (12). The virus stock was prepared by infecting Vero 76 cells (ATCC CRL-1587) until cytopathic effect (CPE) was visible at two days postinoculation.…”

Section: Methodsmentioning

confidence: 99%

“…The virus stock was prepared by infecting Vero 76 cells (ATCC CRL-1587) until cytopathic effect (CPE) was visible at two days postinoculation. The Vero 76 cells were cultured in Minimal Essential Medium (MEM) (Quality Biological), supplemented with 2% (v/v) Fetal Bovine Serum (Sigma), and 50 μg/ml gentamicin (Gemini Bioproducts) (12).…”

Section: Cell Lines and Virusmentioning

confidence: 99%

“…EID is currently used as an oral dietary supplement to support a healthy thyroid function and is non-toxic, non-allergic and lends itself to prolonged continuous use if kept within the daily recommended upper limit of 1100 μg. Its potential for use in protecting against the transmission of SARS-CoV-2 virus during elective surgical procedures in ophthalmology, otolaryngology and dental has been demonstrated recently using PVP-I solutions (12). Whilst steps are already being made to make Essential Iodine Drops (EID) available for nasal administration, the present study was conducted to ascertain whether the EID solution is effective in deactivating SARS-CoV-2 in vitro , as demonstrated with PVP-I.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

In Vitro Efficacy of “Essential Iodine Drops” Against Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2)

Köntös¹

2020

Preprint

View full text Add to dashboard Cite

BackgroundAerosolization of respiratory droplets is considered the main route of coronavirus disease 2019 (COVID-19). Therefore, reducing the viral load of Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2) shed via respiratory droplets is potentially an ideal strategy to prevent the spread of the pandemic. The in vitro virucidal activity of intranasal Povidone-Iodine (PVP-I) has been demonstrated recently to reduce SARS-CoV-2 viral titres. This study evaluated the virucidal activity of the aqueous solution of Iodine-V (a clathrate complex formed by elemental iodine and fulvic acid) as in Essential Iodine Drops (EID) with 200 μg elemental iodine/ml content against SARS-CoV-2 to ascertain whether it is a better alternative to PVP-I.MethodsSARS-CoV-2 (USAWA1/2020 strain) virus stock was prepared by infecting Vero 76 cells (ATCC CRL-1587) until cytopathic effect (CPE). The virucidal activity of EID against SARS-CoV-2 was tested in three dilutions (1:1; 2:1 and 3:1) in triplicates by incubating at room temperature (22 ± 2°C) for either 60 or 90 seconds. The surviving viruses from each sample were quantified by a standard end-point dilution assay.ResultsEID (200 μg iodine/ml) after exposure for 60 and 90 seconds was compared to controls. In both cases, the viral titre was reduced by 99% (LRV 2.0). The 1:1 dilution of EID with virus reduced SARS-CoV-2 virus from 31,623 cell culture infectious dose 50% (CCCID50) to 316 CCID50 within 90 seconds.ConclusionSubstantial reductions in LRV by Iodine-V in EID confirmed the activity of EID against SARS-CoV-2 in vitro, demonstrating that Iodine-V in EID is effective at inactivating the virus in vitro and therefore suggesting its potential application intranasally to reduce SARS-CoV-2 transmission from known or suspected COVID-19 patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Cell Lines and Virusmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

In Vitro Efficacy of “Essential Iodine Drops” Against Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2)

Köntös¹

2020

Preprint

View full text Add to dashboard Cite

show abstract

“…13 and povidone-iodine have demonstrable virucidal activity. 15,16 Thus, addition of antimicrobial agents to dental unit water lines (DUWLs) offers another possible avenue for minimising microbial contamination of aerosols. Commissioning of future research to mitigate the effects of AGPs in dentistry will also need to account for costs, health and safety concerns, and research ethics.…”

Section: Summary Review/covid-19mentioning

confidence: 99%

Evidence-based strategies to reduce contamination from aerosolised microbes in dental practice environment

Ali

Raja

2020

Evid Based Dent

View full text Add to dashboard Cite

Cohort selection The aim was to evaluate interventions to minimise microbial contamination from aerosol generating procedures in the dental office. Seven electronic databases were searched using key words such as 'aerosols', 'droplets', 'spatter', 'microbial loads' etc to identify relevant randomised controlled trials and prospective non-randomised clinical trials until 6 April 2020. Data sources PubMed; Scopus; Cochrane Central Register of Controlled Trials; Cochrane Database of Systematic Reviews; Open Grey; ClinicalTrials.gov; National Research Register; and hand searches. Data analysis Eligible studies were analysed for effectiveness of various interventions on the microbial counts in the aerosols generated in the dental office using predefined criteria. Data were analysed for assessment of quality of evidence and confidence in the estimated effect, risk of bias and other analyses using Stata 15.1 software. PRISMA guidelines extension for network meta-analysis were followed for reporting. Results Initial search identified 266 studies, of which 35 were evaluated for full text. Finally, 29 studies fulfilled the eligibility criteria for qualitative synthesis. The majority of the included studies were published in the last decade, and 21 out of the 29 studies were randomised controlled trials. However, based on comparable procedural settings (study design, study populations, interventions and outcome measures), only 11 were eligible for contribution to the network meta-analysis. The setting of all interventions was ultrasonic scaling of adult patients in a clinical dental practice environment, and involved 16 direct and 29 indirect comparisons. A multivariate meta-analysis showed pre-procedural mouth rinse with tempered chlorhexidine 0.2% at 47°C was most effective in reducing post-procedural bacterial load compared to the control. A mean difference of -0.92 (95% CI -15.4 to -0.29) in log10 colony-forming units was observed in air samples within 90 cm of the dental unit. Conclusions Notwithstanding the limitations of this network meta-analysis, pre-procedural mouth rinse with tempered chlorhexidine appears to be most effective in reducing bacterial counts in aerosols generated during dental operative procedures. Further randomised controlled clinical trials based on robust designs are required to establish the effectiveness of antimicrobial agents in reducing aerosol-related microbial loads (bacteria and viruses) in clinical environments.

show abstract

Coronavirus Visual Dashboard and Data Repository: COVID-19

Arvindhan

Bhatia

Sinha

et al. 2022

Applications of Computational Methods in Manufacturing and Product Design

View full text Add to dashboard Cite

Efficacy of Povidone-Iodine Nasal And Oral Antiseptic Preparations Against Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2)

Cited by 27 publications

References 28 publications

In Vitro Efficacy of “Essential Iodine Drops” Against Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2)

In Vitro Efficacy of “Essential Iodine Drops” Against Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2)

Evidence-based strategies to reduce contamination from aerosolised microbes in dental practice environment

Coronavirus Visual Dashboard and Data Repository: COVID-19

Contact Info

Product

Resources

About